Glaukos Corporation (GKOS)
NYSE: GKOS · Real-Time Price · USD
178.27
-0.61 (-0.34%)
Oct 26, 2026, 4:00 PM EDT - Market closed
Glaukos Revenue
Glaukos had revenue of $185.61M in the quarter ending June 30, 2026, with 49.54% growth. This brings the company's total for the last twelve months to $612.84M, up 41.55% year-over-year. In the year 2025, Glaukos had annual revenue of $507.44M with 32.33% growth. That makes Glaukos the 10,072nd largest company in the world by revenue and 2,157th in the United States.
Revenue (ttm)
$612.84M
Revenue Growth
+41.55%
P/S Ratio
17.13
Revenue / Employee
$560,182
Employees
1,094
Market Cap
10.51B
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full Glaukos breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 507.44M | 123.96M | 32.33% |
| Dec 31, 2024 | 383.48M | 68.77M | 21.85% |
| Dec 31, 2023 | 314.71M | 31.85M | 11.26% |
| Dec 31, 2022 | 282.86M | -11.15M | -3.79% |
| Dec 31, 2021 | 294.01M | 69.05M | 30.70% |
| Dec 31, 2020 | 224.96M | -12.03M | -5.07% |
| Dec 31, 2019 | 236.98M | 55.71M | 30.73% |
| Dec 31, 2018 | 181.28M | 22.02M | 13.83% |
| Dec 31, 2017 | 159.25M | 44.86M | 39.21% |
| Dec 31, 2016 | 114.40M | 42.70M | 59.55% |
| Dec 31, 2015 | 71.70M | 26.11M | 57.28% |
| Dec 31, 2014 | 45.59M | 24.64M | 117.64% |
| Dec 31, 2013 | 20.95M | 18.52M | 762.33% |
| Dec 31, 2012 | 2.43M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Zimmer Biomet Holdings | 8.51B |
| Smith & Nephew | 6.30B |
| STERIS | 6.04B |
| Bruker | 3.50B |
| Globus Medical | 3.14B |
| Insulet | 3.05B |
| Bio-Rad Laboratories | 2.59B |
| Bio-Rad Laboratories | 2.59B |
GKOS News
- 13 days ago - Glaukos price target raised to $190 from $185 at Mizuho - TheFly
- 14 days ago - Glaukos price target raised to $205 from $202 at BTIG - TheFly
- 17 days ago - Glaukos announces Phase 4 trial of iDose TR met primary efficacy endpoint - TheFly
- 17 days ago - Glaukos Announces Positive Topline Results from Phase 4 Prospective Randomized Controlled Clinical Trial Evaluating iDose® TR in Combination with Cataract Surgery - Business Wire
- 18 days ago - Glaukos falls -7.4% - TheFly
- 18 days ago - Glaukos announces exclusive license agreement with RevOpsis for RO-104 - TheFly
- 18 days ago - Glaukos Announces Exclusive License Agreement with RevOpsis Therapeutics to Develop and Commercialize RO-104, a First-in-Class Tri-Specific Biologic for Retinal Diseases - Business Wire
- 19 days ago - Glaukos says late-stage eye disease treatment shows lasting benefits after single dose - Reuters